|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wu M, Huang Y, Chen T, Wang W, Yang S, Ye
Z and Xi X: LncRNA MEG3 inhibits the progression of prostate cancer
by modulating miR-9-5p/QKI-5 axis. J Cell Mol Med. 23:29–38. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gillessen S, Omlin A, Attard G, de Bono
JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith
MR, et al: Management of patients with advanced prostate cancer:
Recommendations of the St Gallen advanced prostate cancer consensus
conference (APCCC) 2015. Ann Oncol. 26:1589–1604. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Taghizadeh H, Marhold M, Tomasich E,
Udovica S, Merchant A and Krainer M: Immune checkpoint inhibitors
in mCRPC-rationales, challenges and perspectives. Oncoimmunology.
8:e16441092019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Löffeler S, Weedon-Fekjaer H, Wang-Hansen
MS, Sebakk K, Hamre H, Haug ES and Fosså SD: ‘Natural course’ of
disease in patients with metastatic castrate-resistant prostate
cancer: Survival and prognostic factors without life-prolonging
treatment. Scand J Urol. 49:440–445. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Heidenreich A, Pfister D, Merseburger A
and Bartsch G; German Working Group on Castration-Resistant
Prostate Cancer (GWG-CRPC), : Castration-resistant prostate cancer:
Where we stand in 2013 and what urologists should know. Eur Urol.
64:260–265. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Culp MB, Soerjomataram I, Efstathiou JA,
Bray F and Jemal A: Recent global patterns in prostate cancer
incidence and mortality rates. Eur Urol. 77:38–52. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Root A, Beizaei A and Ebhardt HA:
Structure-based assessment and network analysis of targeting 14-3-3
proteins in prostate cancer. Mol Cancer. 17:1562018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Aghazadeh Y and Papadopoulos V: The role
of the 14-3-3 protein family in health, disease, and drug
development. Drug Discov Today. 21:278–287. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Neal CL, Xu J, Li P, Mori S, Yang J, Neal
NN, Zhou X, Wyszomierski SL and Yu D: Overexpression of 14-3-3ζ in
cancer cells activates PI3K via binding the p85 regulatory subunit.
Oncogene. 31:897–906. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Peng H, Wang L, Su Q, Yi K, Du J and Wang
Z: MiR-31-5p promotes the cell growth, migration and invasion of
colorectal cancer cells by targeting NUMB. Biomed Pharmacother.
109:208–216. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Arias N, Aguirre L, Fernández-Quintela A,
González M, Lasa A, Miranda J, Macarulla MT and Portillo MP:
Erratum to: MicroRNAs involved in the browning process of
adipocytes. J Physiol Biochem. 72:523–524. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ahn J, Lee H, Chung CH and Ha T: High fat
diet induced downregulation of microRNA-467b increased lipoprotein
lipase in hepatic steatosis. Biochem Biophys Res Commun.
414:664–669. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sur S, Steele R, Shi X and Ray RB:
miRNA-29b inhibits prostate tumor growth and induces apoptosis by
increasing bim expression. Cells. 8:14552019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kirimura S, Kurata M, Nakagawa Y, Onishi
I, Abe-Suzuki S, Abe S, Yamamoto K and Kitagawa M: Role of
microRNA-29b in myelodysplastic syndromes during transformation to
overt leukaemia. Pathology. 48:233–241. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang B, Shetti D, Fan C and Wei K:
miR-29b-3p promotes progression of MDA-MB-231 triple-negative
breast cancer cells through downregulating TRAF3. Biol Res.
52:382019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ding D, Li C, Zhao T, Li D, Yang L and
Zhang B: LncRNA H19/miR-29b-3p/PGRN axis promoted
epithelial-mesenchymal transition of colorectal cancer cells by
acting on wnt signaling. Mol Cells. 41:423–435. 2018.PubMed/NCBI
|
|
18
|
Liu D, Wang J and Liu M: Long noncoding
RNA TUG1 promotes proliferation and inhibits apoptosis in multiple
myeloma by inhibiting miR-29b-3p. Biosci Rep. 39:BSR201824892019.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mao A, Tang J, Tang D, Wang F, Liao S,
Yuan H, Tian C, Sun C, Si J, Zhang H and Xia X: MicroRNA-29b-3p
enhances radiosensitivity through modulating WISP1-mediated
mitochondrial apoptosis in prostate cancer cells. J Cancer.
11:6356–6364. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Worst TS, Previti C, Nitschke K, Diessl N,
Gross JC, Hoffmann L, Frey L, Thomas V, Kahlert C, Bieback K, et
al: miR-10a-5p and miR-29b-3p as extracellular vesicle-associated
prostate cancer detection markers. Cancers (Basel). 12:432019.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lyu J, Zhao L, Wang F, Ji J, Cao Z, Xu H,
Shi X, Zhu Y, Zhang C, Guo F, et al: Discovery and validation of
serum MicroRNAs as early diagnostic biomarkers for prostate cancer
in chinese population. Biomed Res Int. 2019:93068032019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao J, Xu H, Duan Z, Chen X, Ao Z, Chen
Y, Ruan Y and Ni M: miR-31-5p regulates 14-3-3 ε to inhibit
prostate cancer 22RV1 cell survival and proliferation via
PI3K/AKT/Bcl-2 signaling pathway. Cancer Manag Res. 12:6679–6694.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Min S, Liang X, Zhang M, Zhang Y, Mei S,
Liu J, Liu J, Su X, Cao S, Zhong X, et al: Multiple
tumor-associated microRNAs modulate the survival and longevity of
dendritic cells by targeting YWHAZ and Bcl2 signaling pathways. J
Immunol. 190:2437–2446. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu D, Yi B, Liao Z, Tang L, Yin D, Zeng
S, Yao J and He M: 14-3-3γ protein attenuates
lipopolysaccharide-induced cardiomyocytes injury through the Bcl-2
family/mitochondria pathway. Int Immunopharmacol. 21:509–515. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jiang H, Zhang G, Wu JH and Jiang CP:
Diverse roles of miR-29 in cancer (review). Oncol Rep.
31:1509–1516. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li Y, Cai B, Shen L, Dong Y, Lu Q, Sun S,
Liu S, Ma S, Ma PX and Chen J: MiRNA-29b suppresses tumor growth
through simultaneously inhibiting angiogenesis and tumorigenesis by
targeting Akt3. Cancer Lett. 397:111–119. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang H, Guan X, Tu Y, Zheng S, Long J, Li
S, Qi C, Xie X, Zhang H and Zhang Y: MicroRNA-29b attenuates
non-small cell lung cancer metastasis by targeting matrix
metalloproteinase 2 and PTEN. J Exp Clin Cancer Res. 34:592015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li Y, Zhang Z, Xiao Z, Ying L, Luo T, Zhou
Q and Zhang X: Chemotherapy-mediated miR-29b expression inhibits
the invasion and angiogenesis of cervical cancer. Oncotarget.
8:14655–14665. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Inoue A, Yamamoto H, Uemura M, Nishimura
J, Hata T, Takemasa I, Ikenaga M, Ikeda M, Murata K, Mizushima T,
et al: MicroRNA-29b is a novel prognostic marker in colorectal
cancer. Ann Surg Oncol. 22 (Suppl 3):S1410–S1418. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li L, Guo Y, Chen Y, Wang J, Zhen L, Guo
X, Liu J and Jing C: The diagnostic efficacy and biological effects
of microRNA-29b for colon cancer. Technol Cancer Res Treat.
15:772–779. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Basati G, Razavi AE, Pakzad I and Malayeri
FA: Circulating levels of the miRNAs, miR-194, and miR-29b, as
clinically useful biomarkers for colorectal cancer. Tumour Biol.
37:1781–1788. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Papachristopoulou G, Papadopoulos EI,
Nonni A, Rassidakis GZ and Scorilas A: Expression analysis of
miR-29b in malignant and benign breast tumors: A promising
prognostic biomarker for invasive ductal carcinoma with a possible
histotype-related expression status. Clin Breast Cancer.
18:305–312.e3. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hong Q, Fang J, Pang Y and Zheng J:
Prognostic value of the microRNA-29 family in patients with primary
osteosarcomas. Med Oncol. 31:372014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Moore BW, Perez VJ and Gehring M: Assay
and regional distribution of a soluble protein characteristic of
the nervous system. J Neurochem. 15:265–272. 1968. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang YF, Lee YC, Wang YY, Wang CH, Hou MF
and Yuan SF: YWHAE promotes proliferation, metastasis, and
chemoresistance in breast cancer cells. Kaohsiung J Med Sci.
35:408–416. 2019.PubMed/NCBI
|
|
36
|
Yan L, Gu H, Li J, Xu M, Liu T, Shen Y,
Chen B and Zhang G: RKIP and 14-3-3ε exert an opposite effect on
human gastric cancer cells SGC7901 by regulating the ERK/MAPK
pathway differently. Dig Dis Sci. 58:389–396. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu TA, Jan YJ, Ko BS, Liang SM, Chen SC,
Wang J, Hsu C, Wu YM and Liou JY: 14-3-3ε overexpression
contributes to epithelial-mesenchymal transition of hepatocellular
carcinoma. PLoS One. 8:e579682013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhu C, Hou X, Zhu J, Jiang C and Wei W:
Expression of miR-30c and miR-29b in prostate cancer and its
diagnostic significance. Oncol Lett. 16:3140–3144. 2018.PubMed/NCBI
|
|
39
|
Ru P, Steele R, Newhall P, Phillips NJ,
Toth K and Ray RB: miRNA-29b suppresses prostate cancer metastasis
by regulating epithelial-mesenchymal transition signaling. Mol
Cancer Ther. 11:1166–1173. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yan B, Guo Q, Fu FJ, Wang Z, Yin Z, Wei YB
and Yang JR: The role of miR-29b in cancer: Regulation, function,
and signaling. Onco Targets Ther. 8:539–548. 2015.PubMed/NCBI
|
|
41
|
Yan B, Guo Q, Nan XX, Wang Z, Yin Z, Yi L,
Wei YB, Gao YL, Zhou KQ and Yang JR: Micro-ribonucleic acid 29b
inhibits cell proliferation and invasion and enhances cell
apoptosis and chemotherapy effects of cisplatin via targeting of
DNMT3b and AKT3 in prostate cancer. Onco Targets Ther. 8:557–565.
2015.PubMed/NCBI
|
|
42
|
Mann J, Githaka JM, Buckland TW, Yang N,
Montpetit R, Patel N, Li L, Baksh S, Godbout R, Lemieux H and
Goping IS: Non-canonical BAD activity regulates breast cancer cell
and tumor growth via 14-3-3 binding and mitochondrial metabolism.
Oncogene. 38:3325–3339. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kulsoom B, Shamsi TS, Afsar NA, Memon Z,
Ahmed N and Hasnain SN: Bax, Bcl-2, and Bax/Bcl-2 as prognostic
markers in acute myeloid leukemia: Are we ready for Bcl-2-directed
therapy? Cancer Manag Res. 10:403–416. 2018. View Article : Google Scholar : PubMed/NCBI
|
